At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Polyphenon Edrug
Likely dose
Polyphenon E 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression
Louisiana State University Health Sciences Center Shreveport·interventional·Posted May 13, 2008·Updated Sep 21, 2017
In Brief
A Phase 2 clinical trial evaluating Polyphenon E for Breast Cancer. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
To see if an extract of green tea can affect certain markers of breast cancer and breast cancer progression in women with a recent biopsy positive for cancer and who are scheduled for surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsColumbia University
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
First PostedMay 2008
Primary CompletionDec 2009
Study CompletionJul 2013
TodayJul 2026
First PostedMay 13, 2008
Enrollment StartMay 1, 2004
Primary CompletionDec 1, 2009
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 18.1 years ago
Interventions
Polyphenon Edrug
Four 200mg capsules daily taken with a meal, for the duration of the study.